Literature DB >> 21144873

A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication.

Yang Wu1, Qingjiao Liao, Rongge Yang, Xinwen Chen, Xulin Chen.   

Abstract

Herein, we describe the development of a monocistronic dual reporter virus for monitoring hepatitis C virus (HCV) replication. The recombinant construct encodes for the humanized Renilla luciferase (hRLuc) reporter gene inserted upstream of the viral open reading frame and a green fluorescent protein (GFP) gene inserted into the C-terminus of non-structural protein 5A (NS5A) of the JFH1 viral genome. The viral RNA replicated efficiently in transfected cells and infectious virions could be produced without obvious attenuation of viral replication. The viral titer of the dual reporter virus was comparable to that of single reporter viruses. The expression levels of these two reporter genes correlated well with HCV replication in the presence or absence of antiviral agents. Moreover, because of the direct visibility of GFP fluorescence and the correlation between GFP positive cell numbers and hRLuc activity, the optimal time for measuring hRLuc activity was determined. This novel infectious system is a time saving and cost effective method for studying the interaction between viruses and host cells as well as for screening anti-HCV drugs. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144873     DOI: 10.1016/j.virusres.2010.11.009

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Cytosolic phospholipase A2 gamma is involved in hepatitis C virus replication and assembly.

Authors:  Song Xu; Rongjuan Pei; Min Guo; Qingxia Han; Juan Lai; Yun Wang; Chunchen Wu; Yuan Zhou; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 2.  New hepatitis C virus drug discovery strategies and model systems.

Authors:  Snawar Hussain; Naina Barretto; Susan L Uprichard
Journal:  Expert Opin Drug Discov       Date:  2012-08-04       Impact factor: 6.098

3.  Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Authors:  Xin Tao; Ningyu Wang; Jianfei Wang; Zhifei Fu; Zhengxian Gu; Yang Zhang; Shuhui Chen; Lichun Wang; Luoting Yu
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

4.  Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.

Authors:  Judith M Gottwein; Tanja B Jensen; Christian K Mathiesen; Philip Meuleman; Stephanie B N Serre; Jacob B Lademann; Lubna Ghanem; Troels K H Scheel; Geert Leroux-Roels; Jens Bukh
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

5.  MEAN inhibits hepatitis C virus replication by interfering with a polypyrimidine tract-binding protein.

Authors:  Jihua Xue; Yanning Liu; Ying Yang; Shanshan Wu; Ying Hu; Fan Yang; Xiaotang Zhou; Jing Wang; Feng Chen; Min Zheng; Haihong Zhu; Zhi Chen
Journal:  J Cell Mol Med       Date:  2016-03-01       Impact factor: 5.310

6.  Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot.

Authors:  Jae-Su Moon; Seung-Hoon Lee; Eun-Jung Kim; Hee Cho; Wooseong Lee; Geon-Woo Kim; Hyun-Ji Park; Seung-Woo Cho; Choongho Lee; Jong-Won Oh
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

7.  Vibrio vulnificus quorum-sensing molecule cyclo(Phe-Pro) inhibits RIG-I-mediated antiviral innate immunity.

Authors:  Wooseong Lee; Seung-Hoon Lee; Minwoo Kim; Jae-Su Moon; Geon-Woo Kim; Hae-Gwang Jung; In Hwang Kim; Ji Eun Oh; Hi Eun Jung; Heung Kyu Lee; Keun Bon Ku; Dae-Gyun Ahn; Seong-Jun Kim; Kun-Soo Kim; Jong-Won Oh
Journal:  Nat Commun       Date:  2018-04-23       Impact factor: 14.919

8.  The antiviral activity of poly-γ-glutamic acid, a polypeptide secreted by Bacillus sp., through induction of CD14-dependent type I interferon responses.

Authors:  Wooseong Lee; Seung-Hoon Lee; Dae-Gyun Ahn; Hee Cho; Moon-Hee Sung; Seung Hyun Han; Jong-Won Oh
Journal:  Biomaterials       Date:  2013-09-06       Impact factor: 12.479

9.  In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

Authors:  Somayeh Sadeghi; Negar Seyed; Mohammad-Hossein Etemadzadeh; Saeid Abediankenari; Sima Rafati; Tahereh Taheri
Journal:  Korean J Parasitol       Date:  2015-08-25       Impact factor: 1.341

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.